Published in Histopathology on February 01, 2000
The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A (2003) 4.41
TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest (2003) 3.01
Restoration of TGF-beta signalling reduces tumorigenicity in human lung cancer cells. Br J Cancer (2005) 2.37
Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest (2009) 1.68
Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta. Breast Cancer Res (2000) 1.54
Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res (2007) 1.42
Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat (2008) 1.41
TGF-β - an excellent servant but a bad master. J Transl Med (2012) 1.41
Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. J Clin Invest (2013) 1.37
Loss of TGF-beta or Wnt5a results in an increase in Wnt/beta-catenin activity and redirects mammary tumour phenotype. Breast Cancer Res (2009) 1.29
TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. Cancer Discov (2011) 1.26
Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival. Br J Cancer (2006) 1.21
Expression of TGF-beta signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics. Breast Cancer Res Treat (2009) 1.20
Hyaluronan attenuates transforming growth factor-beta1-mediated signaling in renal proximal tubular epithelial cells. Am J Pathol (2004) 1.13
Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk. Breast Cancer Res (2012) 1.05
Identification of a novel TGFβ/PKA signaling transduceome in mediating control of cell survival and metastasis in colon cancer. PLoS One (2011) 1.05
The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling. Carcinogenesis (2009) 1.02
Erbin and the NF2 tumor suppressor Merlin cooperatively regulate cell-type-specific activation of PAK2 by TGF-beta. Dev Cell (2009) 0.95
Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death. J Biol Chem (2011) 0.95
MicroRNA-301a promotes migration and invasion by targeting TGFBR2 in human colorectal cancer. J Exp Clin Cancer Res (2014) 0.95
Transforming growth factor-β suppresses metastasis in a subset of human colon carcinoma cells. BMC Cancer (2012) 0.92
Evaluation of the prognostic value of TGF-β superfamily type I receptor and TGF-β type II receptor expression in nasopharyngeal carcinoma using high-throughput tissue microarrays. J Mol Histol (2012) 0.92
Epigenetic Targeting of Transforming Growth Factor β Receptor II and Implications for Cancer Therapy. Mol Cell Pharmacol (2009) 0.90
TGF- β: an important mediator of allergic disease and a molecule with dual activity in cancer development. J Immunol Res (2014) 0.85
Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis. Breast Cancer Res (2014) 0.82
Association of overexpression of TIF1γ with colorectal carcinogenesis and advanced colorectal adenocarcinoma. World J Gastroenterol (2011) 0.82
Investigation of three new mouse mammary tumor cell lines as models for transforming growth factor (TGF)-beta and Neu pathway signaling studies: identification of a novel model for TGF-beta-induced epithelial-to-mesenchymal transition. Breast Cancer Res (2004) 0.80
Distinctive mechanism for sustained TGF-β signaling and growth inhibition: MEK1 activation-dependent stabilization of type II TGF-β receptors. Mol Cancer Res (2010) 0.80
TR4 nuclear receptor increases prostate cancer invasion via decreasing the miR-373-3p expression to alter TGFβR2/p-Smad3 signals. Oncotarget (2015) 0.79
TGFβ isoforms and receptors mRNA expression in breast tumours: prognostic value and clinical implications. BMC Cancer (2015) 0.79
Increased pSmad2 expression and cytoplasmic predominant presence of TGF-βRII in breast cancer tissue are associated with poor prognosis: results from the Shanghai Breast Cancer Study. Breast Cancer Res Treat (2014) 0.78
A functional polymorphism of TGFBR2 is associated with risk of breast cancer with ER(+), PR(+), ER(+)PR(+) and HER2(-) expression in women. Oncol Lett (2011) 0.77
Transforming growth factor beta and its receptors: their role in breast cancer. Histopathology (2000) 0.77
Clinical Implications of TβRII Expression in Breast Cancer. PLoS One (2015) 0.76
Expression of CDKN1A/p21 and TGFBR2 in breast cancer and their prognostic significance. Int J Clin Exp Pathol (2015) 0.76
Transforming growth factors-beta are not good biomarkers of chemopreventive efficacy in a preclinical breast cancer model system. Breast Cancer Res (2000) 0.75
Is telomerase reactivation associated with the down-regulation of TGF beta receptor-II expression in human breast cancer? Cancer Cell Int (2003) 0.75
Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet (2001) 17.43
Power and sample size calculations. A review and computer program. Control Clin Trials (1990) 9.58
Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med (1985) 7.22
Enzyme recruitment in evolution of new function. Annu Rev Microbiol (1976) 6.95
Acute enterocolitis in a human being infected with the protozoan Cryptosporidium. Gastroenterology (1976) 6.15
Power and sample size calculations for studies involving linear regression. Control Clin Trials (1998) 5.84
Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell (2001) 5.84
Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem (2000) 5.00
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med (1997) 4.98
The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene (2000) 4.90
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 4.67
BRCA1 is secreted and exhibits properties of a granin. Nat Genet (1996) 4.26
Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer (1985) 3.92
Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Clin Pathol (2000) 3.55
Growth retardation and tumour inhibition by BRCA1. Nat Genet (1996) 3.47
Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol (1992) 3.39
Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer (1993) 3.33
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res (2001) 3.18
Creation of "amyloid" fibrils from Bence Jones proteins in vitro. Science (1971) 3.14
Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med (1994) 3.09
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet (1995) 2.91
Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med (1991) 2.77
Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med (1995) 2.74
Myocardial changes associated with cardiogenic shock. N Engl J Med (1971) 2.67
Control of aromatic acid biosynthesis in Bacillus subtilis: sequenial feedback inhibition. J Bacteriol (1966) 2.65
Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med (1999) 2.60
A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis (1994) 2.52
Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol (1996) 2.50
Comparative control of a branch-point enzyme in microorganisms. J Bacteriol (1967) 2.39
Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer (1996) 2.33
DACRYO-CYSTO-RHINOSTOMY. Br J Ophthalmol (1946) 2.32
Clinical experience over 48 years with pheochromocytoma. Ann Surg (1999) 2.32
Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol (1999) 2.31
Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res (2000) 2.24
Metabolic interlock. The dual function of a folate pathway gene as an extra-operonic gene of tryptophan biosynthesis. J Biol Chem (1972) 2.20
Expression of mitoses per thousand cells and cell density in breast carcinomas: a proposal. Hum Pathol (1992) 2.18
Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer (1982) 2.17
Hypoproteinemia predicts acute respiratory distress syndrome development, weight gain, and death in patients with sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med (2000) 2.10
Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci U S A (1995) 2.07
Enzymological basis for herbicidal action of glyphosate. Plant Physiol (1982) 2.04
American Joint Committee on Cancer prognostic factors consensus conference. Cancer (1999) 2.02
Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer (1995) 2.01
Infiltrating lobular carcinoma of the breast. Histopathology (1982) 1.98
Amyloid, amyloidosis, and amyloidogenesis. Int Rev Exp Pathol (1976) 1.97
Orthologs and paralogs - we need to get it right. Genome Biol (2001) 1.95
p27/Kip1 mutation found in breast cancer. Cancer Res (1996) 1.94
Invasive breast cancer risk in women with sclerosing adenosis. Cancer (1989) 1.93
Ductal carcinoma in situ of the breast: reproducibility of histological subtype analysis. Hum Pathol (1997) 1.91
Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J (2001) 1.90
Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J Natl Cancer Inst (1997) 1.88
Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. Mod Pathol (2000) 1.88
Dual enzymatic routes to L-tyrosine and L-phenylalanine via pretyrosine in Pseudomonas aeruginosa. J Biol Chem (1977) 1.86
Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res (1998) 1.84
Relation between component parts of fibrocystic disease complex and breast cancer. J Natl Cancer Inst (1978) 1.82
Regulatory enzymes of aromatic amino acid biosynthesis in Bacillus subtilis. I. Purification and properties of 3-deoxy-D-arabino-heptulosonate 7-phosphate synthetase. J Biol Chem (1966) 1.82
Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene (2005) 1.81
The regulation of tryptophan biosynthesis in Pseudomonas aeruginosa. Mol Gen Genet (1973) 1.80
Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol (1989) 1.78
Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proc Natl Acad Sci U S A (1991) 1.77
Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res (1998) 1.76
When and to what end do pathologists agree? J Natl Cancer Inst (1998) 1.76
Minimal solid tumor involvement of regional and distant sites: when is a metastasis not a metastasis? Cancer (1999) 1.73
BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem (1999) 1.71
Invasion and metastasis of a mammary tumor involves TGF-beta signaling. Int J Cancer (2001) 1.70
Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst (2001) 1.68
Metabolic interlock. Regulatory interactions exerted between biochemical pathways. J Biol Chem (1969) 1.67
Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst (1999) 1.67
Chloroplasts of higher plants synthesize L-phenylalanine via L-arogenate. Proc Natl Acad Sci U S A (1986) 1.65
Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol (1991) 1.65
Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst (1995) 1.64
Histologic grading of breast carcinoma. A reproducibility study. Cancer (1994) 1.61